Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$68.26 USD

68.26
6,607,174

-7.52 (-9.92%)

Updated Sep 19, 2025 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

Zacks Equity Research

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

by Zacks Equity Research

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

Zacks Equity Research

Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.

Zacks Equity Research

STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down

by Zacks Equity Research

STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.

Zacks Equity Research

OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.

Zacks Equity Research

Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Zacks Equity Research

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

by Zacks Equity Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Zacks Equity Research

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

by Zacks Equity Research

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

Zacks Equity Research

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

by Zacks Equity Research

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Zacks Equity Research

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.

Zacks Equity Research

AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.

Zacks Equity Research

Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Zacks Equity Research

Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result

by Zacks Equity Research

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.

Zacks Equity Research

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Zacks Equity Research

Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand

by Zacks Equity Research

Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.

Zacks Equity Research

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Zacks Equity Research

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.

Zacks Equity Research

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.

Zacks Equity Research

Why DexCom (DXCM) Might be Well Poised for a Surge

by Zacks Equity Research

DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.

Zacks Equity Research

Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.

Zacks Equity Research

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

by Zacks Equity Research

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.